External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
Open Access
- 16 February 2024
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 41 (2) , 117-129
Abstract
Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients’ counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47–0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95% CI 0.39–0.92; p < 0.001 for both]. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.Keywords
All Related Versions
Funding Information
- Università degli Studi di Parma
This publication has 33 references indexed in Scilit:
- Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed TherapyClinical Genitourinary Cancer, 2017
- Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinomaCancer Medicine, 2016
- Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinomaFuture Oncology, 2016
- Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinomaMedical Oncology, 2016
- Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatmentEuropean Journal of Cancer, 2016
- Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell CarcinomaJournal of Urology, 2014
- The role of HIF1α in renal cell carcinoma tumorigenesisJournal of Molecular Medicine, 2014
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinomaCancer, 2008
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002